双固态mTORC1抑制剂在瘤模型中诱导细胞死亡,mTORC1过度活化
Heng Du1, Yu Chi Yang2, Heng-Jia Liu1
1Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
双硬性mTORC1选择性抑制剂在治疗具有mTORC1过活化的癌症方面表现有前途. 这些新型抑制剂有效地降低瘤生长并诱导亡,通过向4EBP1.1,优于现有的Rapalogs.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 拉巴胺素的酸3-酶/AKT/哺乳动物标 (PI3K/AKT/mTOR) 途径在各种癌症中经常受到失调.
- 拉帕洛克药具有有限的临床益处,可能是由于它们对4EBP1的抑制不足,这是mTORC1.1的关键下游目标.
研究的目的:
- 在临床前癌症模型中,与拉帕洛格相比,研究双硬性mTORC1选择性抑制剂的治疗潜力.
- 为了确定双抑制剂在特征为mTORC1过活性的瘤中是否具有更高的疗效.
主要方法:
- 在增加mTORC1活性的瘤模型中对双硬性mTORC1选择性抑制剂的体外和体内评估.
- 关于瘤生长抑制,4EBP1酸化和亡诱导的双抑制剂,拉巴素和MLN0128的比较分析.
- 进行多组学分析以阐明双抑制剂作用的分子机制.
主要成果:
- 双抑制剂显示出强烈的瘤生长抑制和诱导显著的亡,超过了拉巴素和MLN0128.8.的作用.
- 双抑制剂有效地消除了化4EBP1,与拉帕洛格不同.
- 多组学分析揭示了双抑制剂诱导的广泛分子变化,包括通过减少JUN和PRPS1来选择性抑制de novo purin合成.
结论:
- 双硬性mTORC1选择性抑制剂代表了由mTORC1过度激活驱动的癌症的有希望的治疗策略.
- 用双抑制剂向mTORC1,有效抑制4EBP1和de novo purin合成,这比目前的Rapalog疗法具有潜在的优势.
更多相关视频
06:00Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
Published on: September 13, 2017
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
相关概念视频
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
The Intrinsic Apoptotic Pathway
Inhibition of Cdk Activity
Targeted Cancer Therapies
There are several types of targeted therapies against...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
